<DOC>
	<DOCNO>NCT00705133</DOCNO>
	<brief_summary>Our hypothesis IV SQ Treprostinil improve 6 minute walk distance , hemodynamics quality life patient interstitial lung disease severe secondary pulmonary arterial hypertension .</brief_summary>
	<brief_title>Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Eligible subject must IPF severe PAH document standard care rightheart catheterization ( RHC ) plan receive therapy treprostinil recommend treat physician . 1 . All subject must high resolution CT scan ( HRCT ) diagnostic IPF ( perform part standard care evaluation ) available , biopsy proven histological usual interstitial pneumonia ( UIP ) . 2 . Severe pulmonary arterial hypertension define rest mean pulmonary artery pressure ( mPAP ) &gt; 35 mm Hg ; AND pulmonary vascular resistance ( PVR ) &gt; 3 woodsunits ; AND pulmonary capillary wedge pressure ( PCWP ) &lt; 18 mm Hg rightheart catheterization ( RHC ) perform part standard care evaluation . 3 . All subject must plan receive treprostinil therapy recommend treat physician . 1 . Acute chronic impairment dyspnea ( e.g . angina pectoris , intermittent claudication ) limit ability perform standard care sixminute walk test ( 6MWT ) . 2 . Sixminute walk distance ( 6MWD ) &lt; 50 meter screen baseline standard care evaluation 3 . Standard care pulmonary function test ( PFT ) show forced expiratory volume one second ( FEV1 ) / force vital capacity ( FVC ) ratio &lt; 0.65 4 . Standard care pulmonary function test ( PFT ) show residual volume &gt; 120 % predict 5 . Standard care highresolution chest compute tomography ( HRCT ) show emphysema extent &gt; 30 % 6 . Any investigational therapy part clinical trial indication 30 day screen 7 . Change dose treatment IPF investigational agent ( gamma interferon1b , pirfenidone , etanercept , investigational agent intend treat IPF ) , corticosteroid , cytotoxic agent , within 30 day screen . That , subject agent provide dose stable least 30 day prior enrollment . 8 . Current treatment pulmonary hypertension prostaglandin ( epoprostenol iloprost ) 9 . Change dose treatment PAH ( bosentan , sitaxsentan , ambrisentan , tadalafil , sildenafil , vardenafil , calcium channel blocker , nitrate , digitalis ) , within 30 day screen . That , subject agent provide dose stable least 30 day prior enrollment 10 . Pulmonary rehabilitation initiate within 30 day baseline .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>pulmonary hypertension</keyword>
	<keyword>pulmonary fibrosis</keyword>
	<keyword>interstitial lung disease</keyword>
</DOC>